image
Healthcare - Biotechnology - NASDAQ - US
$ 60.48
0.199 %
$ 1.97 B
Market Cap
-44.47
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one BLTE stock under the worst case scenario is HIDDEN Compared to the current market price of 60.5 USD, Belite Bio, Inc is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one BLTE stock under the base case scenario is HIDDEN Compared to the current market price of 60.5 USD, Belite Bio, Inc is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one BLTE stock under the best case scenario is HIDDEN Compared to the current market price of 60.5 USD, Belite Bio, Inc is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BLTE

image
$70.0$70.0$68.0$68.0$66.0$66.0$64.0$64.0$62.0$62.0$60.0$60.0$58.0$58.0$56.0$56.0$54.0$54.0$52.0$52.0Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
0 REVENUE
0.00%
-40 M OPERATING INCOME
-26.30%
-36.1 M NET INCOME
-14.26%
-29.2 M OPERATING CASH FLOW
2.02%
-111 M INVESTING CASH FLOW
-175411.11%
83.6 M FINANCING CASH FLOW
10.05%
0 REVENUE
0.00%
-11.5 M OPERATING INCOME
-17.63%
-9.49 K NET INCOME
-20.62%
0 OPERATING CASH FLOW
0.00%
0 INVESTING CASH FLOW
0.00%
0 FINANCING CASH FLOW
0.00%
Balance Sheet Belite Bio, Inc
image
Current Assets 147 M
Cash & Short-Term Investments 145 M
Receivables 594 K
Other Current Assets 1.33 M
Non-Current Assets 5.06 M
Long-Term Investments 0
PP&E 965 K
Other Non-Current Assets 4.09 M
95.41 %Total Assets$152.1m
Current Liabilities 6.05 M
Accounts Payable 0
Short-Term Debt 276 K
Other Current Liabilities 5.77 M
Non-Current Liabilities 261 K
Long-Term Debt 261 K
Other Non-Current Liabilities 0
4.37 %91.49 %4.14 %Total Liabilities$6.3m
EFFICIENCY
Earnings Waterfall Belite Bio, Inc
image
Revenue 0
Cost Of Revenue 449 K
Gross Profit -449 K
Operating Expenses 39.5 M
Operating Income -40 M
Other Expenses -3.85 M
Net Income -36.1 M
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)0(449k)(449k)(40m)(40m)4m(36m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-24.79% ROE
-24.79%
-23.76% ROA
-23.76%
-27.33% ROIC
-27.33%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Belite Bio, Inc
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)20212021Jul '21Jul '2120222022Jul '22Jul '2220232023Jul '23Jul '2320242024Jul '24Jul '2420252025
Net Income -36.1 M
Depreciation & Amortization 449 K
Capital Expenditures -151 K
Stock-Based Compensation 8.99 M
Change in Working Capital 1.13 M
Others -2.6 M
Free Cash Flow -29.4 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Belite Bio, Inc
image
Wall Street analysts predict an average 1-year price target for BLTE of $60 , with forecasts ranging from a low of $60 to a high of $60 .
BLTE Lowest Price Target Wall Street Target
60 USD -0.79%
BLTE Average Price Target Wall Street Target
60 USD -0.79%
BLTE Highest Price Target Wall Street Target
60 USD -0.79%
Price
Max Price Target
Min Price Target
Average Price Target
858580807575707065656060555550504545Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 18
6. Ownership
Insider Ownership Belite Bio, Inc
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tinlarebant for the treatment of Stargardt disease (STGD1) based on the previously reported interim data from the ongoing Phase 3 DRAGON trial. There are currently no approved treatments for STGD1. globenewswire.com - 1 month ago
Belite Bio: Investors Face Tricky Decision Ahead Of Key STGD1 Study Readout Belite Bio's lead drug, Tinlarebant, shows promise in rare eye diseases, but pivotal data and regulatory approval remain at least 18 months away in my view. The DRAGON study's interim analysis is encouraging, but assumptions of success are risky given the small STGD1 market and lack of robust clinical data. Belite's $2bn valuation appears to price in success for both STGD1 and GA, yet GA efficacy data is lacking and competition is fierce. seekingalpha.com - 1 month ago
Belite Bio, Inc (BLTE) Q1 2025 Earnings Call Transcript Belite Bio, Inc (NASDAQ:BLTE ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Julie Fallon - Investor Relations Tom Lin - Chairman and Chief Executive Officer Nathan Mata - Chief Scientific Officer Hendrik Scholl - Chief Medical Officer Hao-Yuan Chuang - Chief Financial Officer Conference Call Participants Basma Radwan - Leerink Partners Jennifer Kim - Cantor Yi Chen - HCW Bruce Jackson - Benchmark Michael Okunewitch - Maxim Operator Ladies and gentlemen, thank you for joining us, and welcome to the Belite Bio First Quarter 2025 Earnings Call. After today's prepared remarks, we will host a question-and-answer session. seekingalpha.com - 1 month ago
Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the first quarter ended March 31, 2025, and provided a business update. globenewswire.com - 1 month ago
Belite Bio, Inc to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference May 15th Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com globenewswire.com - 1 month ago
Belite Bio to Participate in Four Upcoming Investor Conferences SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in four upcoming investor conferences. Details of the presentations are as follows: globenewswire.com - 1 month ago
Belite Bio, Inc. (BLTE) Q4 2024 Earnings Call Transcript Belite Bio, Inc. (NASDAQ:BLTE ) Q4 2024 Results Conference Call March 17, 2025 4:30 PM ET Company Participants Julie Fallon - Investor Relations Tom Lin - Chairman and Chief Executive Officer Nathan Mata - Chief Scientific Officer Hendrik Scholl - Chief Medical Officer Hao-Yuan Chuang - Chief Financial Officer Conference Call Participants Jennifer Kim - Cantor Basma Radwan - Leerink Partners Yi Chen - H.C. Wainwright Bruce Jackson - Benchmark Michael Okunewitch - Maxim Group Operator Ladies and gentlemen, thank you for joining us, and welcome to the Belite Bio Fourth Quarter and Full Year 2024 Earnings Conference Call. seekingalpha.com - 3 months ago
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company, today announced that its annual report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2024, as filed with the Securities and Exchange Commission on March 17, 2025, is available through its website (https://www.belitebio.com). Shareholders may receive a hard copy of the annual report free of charge upon request. This press release is being issued pursuant to Nasdaq Listing Rule 5250(d)(1)(C). globenewswire.com - 3 months ago
Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the fourth quarter and full-year ended December 31, 2024, and provided a business update. globenewswire.com - 3 months ago
Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Monday, March 17, 2025, at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update for the fourth quarter and full year ended December 31, 2024. globenewswire.com - 3 months ago
Belite Bio Announces Registered Direct Offering of $15 Million SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc ("BLTE" or the "Company") (Nasdaq: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has entered into a securities purchase agreement with a new, fundamental healthcare investor for the purchase and sale of 258,309 American Depositary Shares (“ADSs”) and warrants to purchase 258,309 ADSs, at a purchase price of $58.07 per ADS and accompanying warrant, pursuant to a registered direct offering, equivalent to today's closing price. The offering is expected to result in gross proceeds of approximately $15 million, before deducting offering expenses, as well as the potential for additional proceeds of approximately $15 million from the exercise of five-year warrants issued in the offering. The closing of the offering is expected to occur on or about February 7, 2025, subject to the satisfaction of customary closing conditions. globenewswire.com - 4 months ago
Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007 TAIPEI CITY, Taiwan, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Lin BioScience (6696. Taiwan OTC), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting acute leukemia that have significant unmet medical needs, today announced that its lead pipeline, LBS-007, has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia. Lin BioScience is currently conducting a phase 1/2 trial in patients with relapsed or resistant acute leukemias in the US, Australia, and Taiwan, and has been granted for orphan drug designation (ODD) for acute myeloid leukemia and acute lymphocytic leukemia by the U.S. FDA. globenewswire.com - 7 months ago
8. Profile Summary

Belite Bio, Inc BLTE

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 1.97 B
Dividend Yield 0.00%
Description Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Contact 5820 Oberlin Drive, San Diego, CA, 92121 https://belitebio.com
IPO Date April 29, 2022
Employees 25
Officers Mr. Hao-Yuan Chuang C.F.A., F.R.M., M.B.A. Chief Financial Officer & Director Dr. Yu-Hsin Lin M.B.A., Ph.D. Chairman of the Board of Directors & Chief Executive Officer Dr. Hendrik P.N. Scholl M.A., M.D., Ph.D. Chief Medical Officer Dr. Nathan L. Mata Ph.D. Chief Scientific Officer